Profile of CYCLACEL PHARMACEUTICALS INC(NASDAQ:CYCC) stock

CYCLACEL PHARMACEUTICALS INC0.7302

NASDAQ:CYCC (12/6/2022, 7:00:01 PM)-0.04 (-5.17%)

After market: 0.736 +0.01 (+0.79%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-09 2022-11-09/amc	Earnings (Next)	03-27 2023-03-27
Ins Owners	1.16%	Inst Owners	18.77%
Market Cap	9.16M	Shares	12.54M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	86
IPO	01-01 1996-01-01

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Company Info

CYCLACEL PHARMACEUTICALS INC

200 Connell Dr Ste 1500

Berkeley Heights NEW JERSEY 07922

P: 19085177330.0

CEO: Spiro Rombotis

Employees: 0

Website: http://www.cyclacel.com/

CYCC News

a month ago - CyclacelCyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma...

a month ago - CyclacelCyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

a month ago - CyclacelCyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

a month ago - CyclacelCyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results

a month ago - CyclacelCyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients...